Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 1;12:5764. doi: 10.1038/s41467-021-26091-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Impact of Treg-specific Cd177-KO on the frequency of Treg cells within different tissues of normal or MC38-tumor-bearing mice (n = 6 for normal WT and n = 7 for KO mice; n = 13 for tumor TI-Treg cells and n = 4 for other tissues from tumor-bearing mice, T: tumor. b The ratios between TI Teff cells – including CD4 Tconv and CD8 T cells – and TI Treg cells in MC38 Tumors (n = 13 biological repeats). c Percentage of Ki-67⁺ T cells relative to total CD45⁺ leukocytes within different tissues from WT or Treg-specific Cd177-KO mice bearing MC38 tumors. Tissues were from similar experiments as in Fig. 5c tumor bearing mice (n = 7 WT and 5 Treg-KO). P-values are indicated when less than 0.05. T, tumor; DLN, draining lymph nodes; LN, non-draining lymph nodes; Sp, Spleen. d, e Heatmap showing gene expression of chemokine receptors within CD177⁺ and CD177⁻ TI Treg cells, using flow-sorted CD177⁺ and CD177⁻ TI Treg cells from 5 human breast cancer specimens (d data adapted from GSE89225 with patient number included), or RNA sequencing of splenic or TI Treg cells from MC-38 tumor bearing WT or Treg-specific Cd177-KO mice (e GSE150420, n = 3 each group; tumor KO group, n = 2). f–i Impact of CD177 on Treg recruitment into tumors. Splenic and thymic Treg cells (1:1 combined) from WT or germline CD177-KO mice of C57BL/6 background were purified (CD4⁺CD25⁺GITR⁺) and adoptively transferred into tumor-bearing congenic CD45.1 mice (f–g MC38; h–i Py8119). The frequency (f, h the number of Treg cells per mg tumor tissues) or viability (g, i percent death determined by Fixable Viability Dye eFluor780) of the recipient (CD45.1⁺) or donor (CD45.2⁺) TI Treg cells was determined using flow cytometry after 72 hrs of transfer (n = 3 WT and 4 KO tumor per group for f, g; n = 4 each group for h, i). j Impact of CD177 on Treg migration towards tumor lysates. Total splenocytes and thymocytes from littermates of WT or germline KO mice were seeded into Boyden chamber with 3 μm pore size, using 10% MC38 tumor homogenate as chemoattractant. Percent Treg migration was calculated using the number of migrated Treg cells divided by the sum of migrated and non-migrated Treg cells, determined by flow cytometry (n = 3 biological repeats). All data are presented mean ± s.t.d. Two-sided unpaired T-test was used for all group comparisons.